Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Solid Biosciences Q3 2026 Results: Net Loss of $53.9M, Loss Widens

Solid Biosciences Inc. reported a significant increase in cash, cash equivalents, and available-for-sale securities, totaling approximately $348.9 million as of September 30, 2026, compared to $187.9 million at year-end 2025. The company's accumulated deficit grew to $1.12 billion, reflecting ongoing losses as it advances its neuromuscular and cardiac clinical candidates.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-53.9-45.8
EPS (diluted, $ a share)$-0.36$-0.48

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: SLDB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Solid Biosciences Inc.: key numbers

Share price
$6.48Close, Nov 16
Market cap
$723M
Shares outstanding
111.61MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Solid Biosciences Inc.

All →
4:05 PM ET Form 4
Insider Selling

Solid Biosciences CMO Gabriel Brooks Sells $24.6K of Stock

Gabriel Brooks, CMO, sold 4,374 shares of Solid Biosciences Inc. at $5.62 a share, worth $24.6K in total on Oct 19, 2026. Shares held after the trade: 97,241 (-4.3%).

Value
$24.6K
Shares
4,374
Price
$5.62
Role
CMO
Holding change
-4.3%
Trade date
Oct 19, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.